To further assess CAPE bioactivity in neurodegenerative disease in vivo, we enrolled Drosophila’s AD model (upstream activating sequences-galactose 4, UAS-GAL4) and scopolamine (SC)-induced amnesia mouse model. This evidence concerns the gene SMC2 and neurodegenerative disease.